As of Monday, the GuruFocus All-in-A person Screener, a Premium feature, uncovered that the subsequent shares have small cost-earnings ratios and have been acquired by gurus. Although some of them are wonderful worth investments, others may possibly will need to be researched extra diligently, according to the discounted income movement calculator.

Bio-Rad Laboratories

With a market cap of $eleven.08 billion, Bio-Rad Laboratories Inc. (BIO) has a cost-earnings ratio of 6.forty three. In accordance to the DCF calculator, the stock has a honest worth of $820 while investing at $374. The stock has attained 21% in excess of the last 12 months and is now nine.three% underneath the 52-week high and 39.26% over the 52-week small.

2492fb3d7a5b1794e887ff2c572174be.png

The firm has a GuruFocus profitability rating of 7 out of 10. The return on fairness of 7.seventy two% and return on belongings of five.fifty four% are outperforming 97% of companies in the health care units and devices business. Its economic energy is rated 7 out of 10. The income-personal debt ratio of 1.71 is over the business median of 1.4.

The company’s greatest expert shareholder is John Rogers (Trades, Portfolio) with .seventy six% of excellent shares, followed by Ken Fisher (Trades, Portfolio) with .75% and NWQ Managers (Trades, Portfolio) with .forty three%.

Ligand Pharmaceuticals

With a $1.7 billion market cap, Ligand Pharmaceuticals Inc. (LGND) is investing with a cost-earnings ratio of three.sixty seven. The share cost has declined three% in excess of the earlier 12 months and is now 17.59% underneath the 52-week high and 27.35% over the 52-week small.

61e6fd076e7307d5daf7cebd073c4d29.png

GuruFocus gave the biopharmaceutical and biotechnology firm a profitability rating of eight out of 10. The return on fairness of seventy three.17% and return on belongings of 39.36% are outperforming ninety eight% of companies in the biotechnology business. Its economic energy is rated 4 out of 10. The income-personal debt ratio of 1.65 is considerably underneath the business median of eight.38.

Jim Simons (Trades, Portfolio)’ Renaissance Systems is the company’s greatest expert shareholder with five.82% of excellent shares, followed by Fisher with .fifty% and Lee Ainslie (Trades, Portfolio)’s Maverick Funds with .09%.

Alexion Pharmaceuticals

With a market cap of $20.three billion, Alexion Pharmaceuticals Inc. (ALXN) is investing with a cost-earnings ratio of eight.57 and a cost-reserve ratio of 1.eighty one. In accordance to the DCF calculator, the stock has a honest worth of $155 while investing at about $91.ninety eight. Shares have tumbled 30% in excess of the last 12 months and are now investing 35.sixteen% underneath the 52-week high and two.ninety nine% over the 52-week small.

073ca9d5008241180e17c3ffef3f9b52.png

The developer of drugs for patients in significant health care ailments has a Gurufocus profitability rank of nine out of 10. The firm’s return on fairness of 23.seventy two% and return on belongings of sixteen.06% are outperforming ninety eight% of companies in the biotechnology business. The income-personal debt ratio of 1.03 is underneath the business median of eight.38.

The company’s greatest expert shareholder is Simons’ company with 1.69% of excellent shares, followed by Pioneer Investments (Trades, Portfolio) with .34% and David Carlson (Trades, Portfolio) with .24%.

Innoviva

Innoviva Inc. (INVA) has a market cap of $1.three billion and is investing with a cost-earnings ratio of nine.29 and a cost-reserve ratio of 4.29. In accordance to the DCF calculator, the stock has a honest worth of $fifteen.30 while investing at about $thirteen.30. Shares have declined 6% in excess of the last 12 months.

88b8fe8311648501f44fe87f2478c261.png

GuruFocus provides the economic providers firm a profitability rating of 6 out of 10. The return on fairness of sixty eight.44% and return on belongings of 24.seventy two% are outperforming ninety eight% of companies in the biotechnology business. Its economic energy is rated five out of 10. The income-personal debt ratio of .ninety three is underneath the business median of eight.38.

With 7.79% of excellent shares, Simons’ company is the company’s greatest expert shareholder, followed by Initially Eagle Financial investment (Trades, Portfolio) with 1.sixty four%.

Arena Pharmaceuticals

Arena Pharmaceuticals Inc. (ARNA) has a market cap of $two.three billion. Its shares are investing with a cost-earnings ratio of 6.02 and a cost-reserve ratio of two.21. In accordance to the DCF calculator, the stock has a honest worth of $eighty one.seventy six while investing at $forty six. Shares prices experienced no web transform in excess of the earlier 12 months and are at this time investing 28.61% underneath the 52-week high and eleven.forty% over the 52-week small.

19ca75018938c8ab6455eccb23b9d643.png

The firm, which is centered on receptors of G-protein-coupled, has a GuruFocus profitability rating of 4 out of 10. The return on fairness of 37.seventy three% and return on belongings of 34.77% are outperforming ninety eight% of companies in the biotechnology business. Its economic energy is rated nine out of 10. The firm has no personal debt.

The company’s greatest expert shareholder is PRIMECAP Administration (Trades, Portfolio) with two.58% of excellent shares, followed by Steven Cohen (Trades, Portfolio)’s Point72 Asset Administration with .65% and John Hussman (Trades, Portfolio) with .09%.

Supernus Pharmaceuticals

Supernus Pharmaceuticals Inc. (SUPN) has a market cap of $913 million. Its shares are investing with a cost-earnings ratio of eight.twenty five and a cost-reserve ratio of 1.58. In accordance to the DCF calculator, the stock has a honest worth of $22.58 while investing at $17.30. Shares have tanked fifty five% in excess of a 12-month interval and are at this time investing 59.61% underneath the 52-week high and three.two% over the 52-week small.

56a20f91928e1cc6065b6a6bdbbc5406.png

The specialty pharmaceutical firm has a GuruFocus profitability rating of 7 out of 10. The return on fairness of 21.sixty seven% and return on belongings of 10.6% are outperforming 84% of companies in the drug makers business. Its economic energy is rated five out of 10. The income-personal debt ratio of .ninety two is underneath the business median of .97.

The company’s greatest expert shareholder is Simons with 1.seventy six% of excellent shares, followed by Robert Bruce (Trades, Portfolio) with .sixty seven% and Chuck Royce (Trades, Portfolio) with .48%.

Disclosure: I do not personal any shares outlined.

Examine extra listed here:

Not a Premium Member of GuruFocus? Indicator up for a free 7-day demo listed here.